ABT Stock Recent News
ABT LATEST HEADLINES
In the latest trading session, Abbott (ABT) closed at $117.11, marking a +0.58% move from the previous day.
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott has launched its over-the-counter continuous glucose monitoring system Lingo in the United States, the company said on Thursday.
Abbott Laboratories launches its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.
Abbott Laboratories on Thursday announced its over-the-counter continuous glucose monitor Lingo is available in the U.S. Lingo can be purchased without a prescription, and it's intended for adults who do not take insulin that want to improve their overall health and wellness.
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating condition Approximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder.
In the latest trading session, Abbott (ABT) closed at $114.66, marking a +1.23% move from the previous day.
Given its better prospects, we believe Abbott stock (NYSE: ABT) is a better pick than its peer Medtronic stock (NYSE: MDT). ABT stock trades at 4.9x trailing revenues, versus 3.6x for MDT.